NASDAQ:PRTA

Prothena (PRTA) Stock Forecast, Price & News

$47.60

+0.30 (+0.63%)

(As of 09/26/2023 ET)

Compare

Today's Range: $45.22
▼
$47.93
50-Day Range: $47.30
▼
$69.05
52-Week Range: $28.99
▼
$79.65

Volume: 576,001 shs
Average Volume: 394,026 shs
Market Capitalization: $2.55 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $87.56

Prothena MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.90 Rating Score
Upside/Downside: 83.9% Upside
$87.56 Price Target
Short Interest: Bearish
7.70% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.19
Based on 9 Articles This Week
Insider Trading: Selling Shares
$4.14 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.99) to ($4.70) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

721st out of 963 stocks

Pharmaceutical Preparations Industry

329th out of 446 stocks

3.5

Analyst's Opinion

Consensus Rating
Prothena has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $87.56, Prothena has a forecasted upside of 83.9% from its current price of $47.60.
Amount of Analyst Coverage
Prothena has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
7.70% of the outstanding shares of Prothena have been sold short.
Short Interest Ratio / Days to Cover
Prothena has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Prothena has recently increased by 11.35%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Prothena does not currently pay a dividend.
Dividend Growth
Prothena does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRTA.

2.1

News and Social Media Coverage

News Sentiment
Prothena has a news sentiment score of -0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Prothena this week, compared to 3 articles on an average week.
Search Interest
7 people have searched for PRTA on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
MarketBeat Follows
1 people have added Prothena to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prothena insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,139,550.00 in company stock.
Percentage Held by Insiders
28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Prothena are expected to decrease in the coming year, from ($2.99) to ($4.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prothena is -17.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prothena is -17.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Prothena has a P/B Ratio of 3.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Prothena (NASDAQ:PRTA) Stock

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Price History

30 days | 90 days | 365 days | Advanced Chart

PRTA Stock News Headlines

September 27, 2023 | americanbankingnews.com

Prothena (NASDAQ:PRTA) Upgraded to "Hold" at StockNews.com

September 23, 2023 | americanbankingnews.com

Prothena Co. plc (NASDAQ:PRTA) to Post Q1 2024 Earnings of ($1.34) Per Share, Zacks Research Forecasts

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 21, 2023 | seekingalpha.com

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

September 20, 2023 | americanbankingnews.com

Prothena (NASDAQ:PRTA) Downgraded by StockNews.com to Sell

September 20, 2023 | finance.yahoo.com

Insider Sell: Karin Walker Sells 5,000 Shares of Prothena Corp PLC

September 16, 2023 | finance.yahoo.com

Pinning Down Prothena Corporation plc's (NASDAQ:PRTA) P/S Is Difficult Right Now

September 14, 2023 | finance.yahoo.com

Insider Sell: Chief Medical Officer Hideki Garren Sells 2,000 Shares of Prothena Corp PLC

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

September 7, 2023 | finance.yahoo.com

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

August 4, 2023 | markets.businessinsider.com

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

August 4, 2023 | markets.businessinsider.com

JMP Securities Maintains Outperform Rating for Prothena Corp: Here's What You Need To Know

August 4, 2023 | finance.yahoo.com

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

August 2, 2023 | benzinga.com

Prothena Corp's Earnings Outlook

August 2, 2023 | finance.yahoo.com

Prothena Corporation plc (NASDAQ:PRTA) Shares Could Be 36% Below Their Intrinsic Value Estimate

July 28, 2023 | finanznachrichten.de

Prothena Corporation plc: Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

July 27, 2023 | seekingalpha.com

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

July 19, 2023 | fool.com

Prothena Plc (NASDAQ: PRTA)

July 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Prothena (PRTA) and Masimo (MASI)

July 11, 2023 | msn.com

Expert Ratings for Prothena Corp

July 11, 2023 | markets.businessinsider.com

Jefferies Keeps Their Buy Rating on Prothena (PRTA)

July 11, 2023 | finance.yahoo.com

Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY

July 11, 2023 | markets.businessinsider.com

Prothena (PRTA) Receives a Buy from Bank of America Securities

July 11, 2023 | markets.businessinsider.com

Prothena (PRTA) Receives a Buy from JMP Securities

July 10, 2023 | businesswire.com

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

July 10, 2023 | bizjournals.com

Peninsula biotech lands $55M as Big Pharma exercises option on Alzheimer's drug

June 21, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Exact Sciences (EXAS) and Prothena (PRTA)

See More Headlines

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Company Calendar

Last Earnings: 8/03/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRTA
CUSIP: N/A
CIK: 1559053
Web: www.prothena.com
Phone: (531) 236-2500
Fax: 353-1902-3510
Employees: 127
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $87.56
High Stock Price Forecast: $129.00
Low Stock Price Forecast: $55.00
Forecasted Upside/Downside: +83.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.90
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-116,950,000.00
Net Margins: -244.45%
Pretax Margin: -266.80%
Return on Equity: -25.43%
Return on Assets: -20.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.46
Quick Ratio: 9.46

Sales & Book Value

Annual Sales: $53.90 million
Price / Sales: 47.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.86 per share
Price / Book: 3.70

Miscellaneous

Outstanding Shares: 53,530,000
Free Float: 38,438,000
Market Cap: $2.55 billion
Optionable: Optionable
Beta: 0.39

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Gene G. Kinney Ph.D. (Age 54)
Pres, CEO & Director
Comp: $1.03M

Mr. Tran B. Nguyen M.B.A. (Age 49)
CFO & Chief Strategy Officer
Comp: $762.86k

Mr. Brandon S. Smith (Age 48)
Chief Operating Officer
Comp: $756.41k

Ms. Carol D. Karp (Age 70)
Chief Regulatory Officer
Comp: $697.51k

Dr. Hideki Garren M.D. (Age 58)
Ph.D., Chief Medical Officer
Comp: $809.59k

Ms. Karin L. Walker CPA (Age 60)
CPA, Chief Accounting Officer & Controller

Dr. Wagner M. Zago (Age 50)
Chief Scientific Officer

Ms. Jennifer Zibuda
Director of Investor Relations & Communication

Mr. Michael J. Malecek (Age 57)
Chief Legal Officer & Company Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRTA Stock - Frequently Asked Questions

Should I buy or sell Prothena stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings or view top-rated stocks.
What is Prothena's stock price forecast for 2023?: 10 analysts have issued 12 month target prices for Prothena's shares. Their PRTA share price forecasts range from $55.00 to $129.00. On average, they predict the company's stock price to reach $87.56 in the next year. This suggests a possible upside of 83.9% from the stock's current price.
View analysts price targets for PRTA or view top-rated stocks among Wall Street analysts.
How have PRTA shares performed in 2023?: Prothena's stock was trading at $60.25 at the start of the year. Since then, PRTA shares have decreased by 21.0% and is now trading at $47.60.
View the best growth stocks for 2023 here.
When is Prothena's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our PRTA earnings forecast.
How were Prothena's earnings last quarter?: Prothena Co. plc (NASDAQ:PRTA) issued its earnings results on Thursday, August, 3rd. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.11. The biotechnology company earned $4.02 million during the quarter, compared to the consensus estimate of $5.09 million. Prothena had a negative trailing twelve-month return on equity of 25.43% and a negative net margin of 244.45%. The company's quarterly revenue was up 206.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.88) earnings per share.
What ETFs hold Prothena's stock?: ETFs with the largest weight of Prothena (NASDAQ:PRTA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Nasdaq Pharmaceuticals ETF (FTXH).

What other stocks do shareholders of Prothena own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).
What is Prothena's stock symbol?: Prothena trades on the NASDAQ under the ticker symbol "PRTA."
Who are Prothena's major shareholders?: Prothena's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.75%), State Street Corp (3.50%), Dimensional Fund Advisors LP (2.15%), Geode Capital Management LLC (1.57%), Bank of New York Mellon Corp (0.97%) and Nuveen Asset Management LLC (0.85%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends.
How do I buy shares of Prothena?: Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Prothena's stock price today?: One share of PRTA stock can currently be purchased for approximately $47.60.
How much money does Prothena make?: Prothena (NASDAQ:PRTA) has a market capitalization of $2.55 billion and generates $53.90 million in revenue each year. The biotechnology company earns $-116,950,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis.
How many employees does Prothena have?: The company employs 127 workers across the globe.
How can I contact Prothena?: Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for the company is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at ellen.rose@prothena.com, or via fax at 353-1902-3510.

This page (NASDAQ:PRTA) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Prothena (PRTA) Stock Forecast, Price & News

Prothena MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Prothena (NASDAQ:PRTA) Stock

PRTA Price History

PRTA Stock News Headlines

PRTA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PRTA Stock - Frequently Asked Questions

Overall MarketRank^™